Kaohsiung Journal of Medical Sciences (Jun 2024)

A comparative analysis of surgically excised hereditary and sporadic pheochromocytomas: Insights from a single‐center experience

  • Narin Nasiroglu Imga,
  • Muzaffer Serdar Deniz,
  • Belma Ozlem Tural Balsak,
  • Yilmaz Aslan,
  • Altug Tuncel,
  • Dilek Berker

DOI
https://doi.org/10.1002/kjm2.12836
Journal volume & issue
Vol. 40, no. 6
pp. 583 – 588

Abstract

Read online

Abstract Pheochromocytoma is a tumor that usually originating from adrenal medullary chromaffin cells and producing one or more catecholamines, can manifest as hereditary or sporadic. While the majority pheochromocytomas are sporadic, hereditary forms are often associated with genetic syndromes such as von Hippel–Lindau, multiple endocrine neoplasia type 2, and neurofibromatosis type 1. This study aims to analyze data from our series of surgically excited pheochromocytoma patients and compare the characteristics between hereditary and sporadic cases. We retrospectively evaluated 33 diagnosed pheochromocytoma patients, documenting clinical features, surgical complications, and tumor characteristics in both hereditary and sporadic cases. Among the patients, 21% (7 individuals) had hereditary pheochromocytoma, while 79% (26 individuals) had sporadic cases. During diagnosis, hereditary pheochromocytoma patients exhibited a significantly lower mean age compared to the sporadic group (26.4 ± 9.9 years vs. 50.4 ± 14.0 years; p < 0.001). The maximum tumor size was also lower in hereditary cases compared to sporadic cases (p = 0.004). Adrenal tumor localization analysis showed that 63.6% were right‐sided, 24.2% were left‐sided, and 12.1% were bilateral. Laboratory analysis revealed significantly higher urinary norepinephrine levels in hereditary pheochromocytoma patients (p = 0.021). Our findings suggest that hereditary pheochromocytoma cases are characterized by a younger age at diagnosis, smaller tumor size, and a higher prevalence of multiple bilateral adrenal adenomas. We recommend genetic testing for all pheochromocytoma patients, particularly those with early‐onset disease and bilateral adrenal tumors.

Keywords